*Disclaimer

AMPLIA THERAPEUTICS LIMITED (ASX: ATX)

🔗 📄 📈

ATX: AMP945 and FOLFIRINOX active in model of Pancreatic Cancer

AMPLIA THERAPEUTICS LIMITED

2023-05-29 08:42:00

ATX: Grant to collaborate with CSIRO Supplementary Announcement

AMPLIA THERAPEUTICS LIMITED

2023-05-23 11:22:00

ATX: Amplia receives grant to collaborate with CSIRO

AMPLIA THERAPEUTICS LIMITED

2023-05-22 08:24:00

ATX: ACCENT Trial Recruitment Progress

AMPLIA THERAPEUTICS LIMITED

2023-05-09 11:44:00

ATX: First Patient Recruited to Cohort 3 of ACCENT Trial

AMPLIA THERAPEUTICS LIMITED

2023-04-19 08:22:00

ATX: Dose Escalation Approved in ACCENT Clinical Trial of AMP945

AMPLIA THERAPEUTICS LIMITED

2023-04-11 12:17:00

ATX: ACCENT Trial Recruitment Progress

AMPLIA THERAPEUTICS LIMITED

2023-02-28 11:29:00

ATX: First Patient Recruited to Cohort 2 of Accent Trial

AMPLIA THERAPEUTICS LIMITED

2023-02-01 11:23:00

ATX: Dose Escalation Approved in ACCENT Clinical Trial of AMP945

AMPLIA THERAPEUTICS LIMITED

  1. The ACCENT clinical trial assessing the efficacy of AMP945 in treating pancreatic cancer patients has now been approved for dose escalation and recruitment of planned second patient cohort.
  2. The Safety Review Committee has examined the available safety, pharmacokinetic and pharmacodynamic data and concluded that dose escalation to a further cohort is warranted.
  3. The first stage of the ACCENT trial is designed to identify the most suitable dose of AMP945 to combine with gemcitabine/nab-paclitaxel chemotherapy in patients with advanced pancreatic cancer.

2023-01-11 13:50:00